Clinical Trial Update: Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

This document describes a Phase 2 trial evaluating serplulimab in combination with SHR-A1811 as neoadjuvant therapy for triple-negative breast cancer. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• SHR-A1811
• Serplulimab (serplulimab)

Snippet

Sponsor: Xijing Hospital | Conditions: Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING